Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech Ltd., a Nasdaq-listed Taiwanese biotechnology company, reaffirmed its global licensing partnership strategy to address the expanding Benign Prostatic Hyperplasia (BPH) market. The company is advancing its botanical drug candidate, Botreso®, currently in Phase III clinical trials in the US and Taiwan, aiming to provide safer, long-term…